House Judiciary Committee Investigates Obamacare Fraud

The House Judiciary Committee has recently issued subpoenas to the chief executives of eight major health insurance companies amid allegations of widespread fraud concerning the enhanced tax credits under Obamacare.

Chairman Jim Jordan (R-Ohio) stated that the committee is looking into the fraud surrounding Obamacare subsidies and whether existing regulatory laws can effectively tackle this issue. He noted that Obamacare established a government-controlled market along with a subsidy system to help individuals purchase healthcare. The inquiry was also supported by Scott Fitzgerald (R-Wis.), chairman of the Administrative State, Regulatory Reform, and Antitrust Subcommittee, and Jeff Van Drew (R-N.J.), chairman of the Oversight Subcommittee.

The committee’s letter emphasizes that the Advanced Premium Tax Credit (APTC)—a subsidy from the federal government to insurance companies—covers premiums surpassing a certain percentage of enrollees’ income. This means that when insurance companies raise premiums, the government pays them more, while consumers remain unaware of these increases when choosing their plans.

Leaders of the House Judiciary Committee highlighted that during the COVID-19 pandemic, the Biden-Harris administration and the Democratic majority enhanced these subsidies, which have since expired and returned to pre-pandemic levels defined by Obamacare.

A report released last December by the General Accounting Office (GAO) indicated a concerning rise in fraud linked to the expanded Obamacare subsidies.

According to the GAO report:

• 58,000 Social Security numbers receiving APTC matched with death data from the Social Security Administration.
• 7,000 individuals had passed away prior to reporting, indicating that their Social Security numbers were incorrectly used in applications.
• The health insurance companies received APTC totaling $94 million on behalf of these deceased individuals.

The letter pointed out that the Trump administration introduced the Market Integrity and Affordability Rule last June to curb Obamacare fraud. However, an injunction from a judge appointed by Biden blocked these anti-fraud initiatives, concluding that the Trump administration did not comply with the Administrative Procedure Act (APA) during the rule’s development. This ruling is currently under appeal.

In light of the widespread fraud, the committee is considering whether reforms to the APA are necessary to expedite the implementation of essential healthcare fraud prevention measures, avoiding excessive administrative burdens. The responses from the health insurance companies will inform potential legislative changes under consideration by the House.